Sun Pharma's $12B binding bid for Organon drives ~20% premarket surge.
According to reports from the Economic Times (cited by Investing.com and others on April 10, 2026), India's Sun Pharmaceutical Industries completed three months of due diligence on Organon and is finalizing a financing package for a firm all-cash offer expected in the coming weeks. This follows earlier 2026 speculation of a roughly $10B deal that Sun had previously called "speculative." The news sent shares from a prior close near $6.91 (after an already strong ~18% gain on April 9) to around $8.28 in premarket trading. Organon did not immediately comment. The potential deal would represent Sun's largest-ever acquisition and significantly expand its women's health and biosimilars portfolio.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.